News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
Inversión biotecnología AseBio
Kadans becomes a new member of the Spanish Association of Science and Technology Parks
Healthcare
Kadans Science Partner, a European leader in innovation campus development, has joined the…
Partners - KADANS SCIENCE PARTNER 1 SP S.L.
El equipo de ALLOX en su laboratorio en el Parque Científico de Barcelona. Foto
ALLOX, the startup exploring allosterism to revolutionize drug development
Healthcare · Access to innovation
Recently established at the Barcelona Science Park, ALLOX is harnessing cutting-edge technology…
Partners - Parc Científic de Barcelona
Repronovo investment YSIOS
Repronovo raises $65 million Series A financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and women’s health
Healthcare · Financing
Round led by Jeito Capital, co-led by AXA IM Alts and M Ventures, with strong syndicate support…
Partners - Ysios Capital Partners
Planta 53 Biologics
Case study: Development of the new GMP plant of 53Biologics
Healthcare
53Biologics strengthens its biopharmaceutical capacity in Spain with a new GMP facility in…
Partners - Klinea Biotech & Pharma Engineering
cdti india.
Gate2Brain secures over €700,000 in CDTI Multipaís funding to advance a novel therapy against pediatric brain tumors in collaboration with India
Healthcare
Gate2Brain secures key funding to advance its groundbreaking pediatric brain tumor therapy
Partners - Gate2Brain
Prevención versus Terapia. El gran avance del siglo actual
Prevention versus Therapy. The breakthrough of the current century
Healthcare
Massive data collection accelerated by the digitisation of healthcare, as well as artificial…
Partners - GENESIS Biomed
Edificio Oryzon
ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)
Healthcare · Rare diseases · Innovative drugs
Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and…
Partners - Oryzon Genomics
Científicos analizando muestras en un laboratorio
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients
Healthcare · Access to innovation · Innovative drugs
Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-…
Oficinas de la compañía biotech Natac
Natac closes 2024 with record sales of nearly 36 million euros
Corporate
The company increased its normalized EBITDA by 47%, reaching €13.82 million.
Partners - Natac Group